Qiagen at Morgan Stanley conference: new ceo outlines focus
On 14 September 2026, Qiagen, a company specializing in laboratory and life sciences tools, presented its updated business strategy at the Morgan Stanley 24th Annual Global Healthcare Conference. Newly appointed CEO Jonathan Pratt aimed to streamline the company, enhance commercial execution, and concentrate capital on a few key priorities.
Qiagen reported holding up better than anticipated, but continued to face challenges from reduced academic spending and a significant decline in immigration-related testing. CEO Jonathan Pratt, who joined two weeks prior to the event, emphasized his background as a scientist and his approach of simplifying complex processes to guide Qiagen's growth.
The company showcased growth in automation, digital PCR, and infectious disease products while maintaining strong margins and cash flow. Analysts view Qiagen as undervalued, trading at a P/E ratio of 21.49, and consider it among the most undervalued stocks.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
